Advancing Psilocybin Drug DevelopmentPsilocin Pharma Corp.
Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body’s own natural pathways of absorption while offering a contemporary approach to consumption.
Revive Therapeutics has partnered with leading institutions for development of Psilocin’s Pharma platform.
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer
Novel discovery and research originated from Universidad Central del Caribe and St. Jude Children’s Research Hospital Medicinal mushroom compound with anticancer activities that have minimal effects on normal cells Showed superior potency against aggressive breast...
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline
Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution for mental illness, substance abuse and neurological disorders Advancing to FDA clinical studies for methamphetamine use disorder and stroke TORONTO, Aug. 10, 2021 -...
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics
TORONTO, June 17, 2021 - Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce...